Success Metrics

Clinical Success Rate

85.7%

Based on 6 completed trials

Completion Rate

86%(6/7)

Active Trials

3(30%)

Results Posted

50%(3 trials)

Terminated

1(10%)

Phase Distribution

Ph phase_2

60%

Ph phase_1

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Phase 1Safety & dosage

4(40.0%)

Phase 2Efficacy & side effects

6(60.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

85.7%

6 of 7 finished

Non-Completion Rate

14.3%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(6)

Terminated(1)

Detailed Status

Completed6

Recruiting3

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

85.7%

Most Advanced

Phase 2

Trials by Phase

Phase 14 (40.0%)

Phase 26 (60.0%)

Trials by Status

terminated110%

completed660%

recruiting330%

Recent Activity

3 active trials

Showing 5 of 10

recruitingphase_1

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

NCT07204574

recruitingphase_2

FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

NCT06988852

recruitingphase_2

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

NCT06640725

completedphase_1

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

NCT01973868

completedphase_2

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

NCT00617734

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT07204574Phase 1

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Recruiting

NCT06988852Phase 2

FOLFOX-HAIC as Conversion Treatment for Initially Unresectable Colorectal Liver Metastasis

Recruiting

NCT06640725Phase 2

Study of TPEx Followed by a Maintenance With Avelumab and Cetuximab in First Line Recurrent or Metastatic Squamous Cell Carcinoma of the H&N

Recruiting

NCT01973868Phase 1

Safety and Pharmacokinetics of Regorafenib and Cetuximab in Combination

Completed

NCT00617734Phase 2

Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck

Completed

NCT02020577Phase 1

Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid Tumours

Completed

NCT00996567Phase 2

A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.

Completed

NCT00660582Phase 2

FLOX + Cetuximab (Erbitux®) for Patients With Metastatic Colorectal Cancer and Wild Type K-RAS Tumor

Completed

NCT00908024Phase 1

Combination Study of BMS-754807 and Erbitux® in Subjects With Advanced or Metastatic Solid Tumors